Background: The CD44is a celladhesion molecule that ispresent as numerous isoforms created by mRNA alternative splicing. Expression of variant isoforms of CD44 is associated with tumor growth and metastasis. The aim of this study was to evaluate whether CD44 isoform expression is a prognostic factor in gastric and colorectal cancer. Methods: We performed a polymerase chain reaction analysis following reverse transcriptase treatment for CD44 expression in fresh surgical specimens obtained from 25 colon carcinomas and 30 gastric carcinomas and matched adjacent normal mucosa. We determined the epithelial variant/hematopoietic variant (E/H) ratio (the amount of the CD44 epithelial variant transcript relative to the CD44 hematopoietic variant transcript) in cancer tissues and examined it for correlations with clinicopathological parameters and survival rate. Results: The E/Hratio intumortissuewassignificantly higherthanthatin adjacent non-cancerous mucosa. In gastric and colorectal cancer tissues, there was no significant relationship between E/Hratio and clinicopathological parameters. However, patients whodieddueto tumorrecurrence had a higher E/H ratio than surviving patients with colorectal cancer. In gastric cancer, patients with high E/H tumors had a shorter survival time than those with low E/H tumors. Conclusions: Our results suggest that the E/H ratio is a useful indicator of prognosis in gastric and colorectal carcinoma.
INTRODUCTION
The CD44 is a cell surface adhesion molecule, originally described as a lymph node homing receptor on circulating lymphocytes (1) . The gene encoding CD44 is found on chromosome 11p. The CD44 protein exists in numerous isoforms generated from the primary transcript by alternative splicing of 10 exons (v I-v 10, 2,3). An isoform lacking all 10 variant exons and termed the hematopoietic form (CD44H) is present on cells of normal epithelial and hematopoietic origin. In contrast, the CD44 alternatively spliced variants are expressed predominantly on Received Apri16, 1998; accepted June 29,1998 For reprints and all correspondence; Yuichi Shibuya, First Department of Surgery, Okayama University Medical School, 2-5-1, Shikata-cho, Okayama 700-0914, Japan Abbreviations: mRNA, messenger ribonucleic acid; CD44E, CD44 epithelial variant; CD44H, CD44 hematopoietic variant; RT, reverse transcriptase; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis cells of tumors. The epithelial variant (CD44E), one of the CD44 variants, contains exons v8-v 10. Recently, CD44 has been postulated to have a role in tumor metastasis. First Gunthert et aI. (4) showed that overexpression of one CD44 variant form, encoded by the cDNA clone pMeta-l, conferred metastatic behavior on a non-metastasizing rat pancreatic carcinoma cell line. Overexpression of the epithelial variant CD44E was found in metastasis of colorectal cancer (5) . Other authors have found that tumor progression is linked to overexpression of exon v6 in colon cancer (6). Guo et aI. (7) reported that serum CD44 concentrations may be an indicator of tumor burden and metastasis in patients with gastric and colon cancer. However, the function of such CD44 isoforms is largely unknown.
In gastric (8) , colorectal (9,10), breast (11) and non-Hodgkin's lymphoma (12) , several studies employing immunohistochemical methods have indicated that CD44 variant isoforms correlate with length of survival, but no studies have been done using molecular biology techniques. In this study, using reverse transcriptase-polymerase chain reaction (RT-PCR), we investigated the E/H ratio (the amount of CD44E transcript relative to CD44H transcript) in surgical specimens of human gastric and colorectaI cancers and matched adjacent normal mucosa. We considered whether the E/H ratio in cancer tissues is a useful indicator of prognosis. Total RNA was extracted by the acid guanidinum-thiocyanatepheno l-chloroform method (13) and reverse transcripted with oligo dT primers, using MoMuLV reverse transcriptase , for 60 min at 37°C (14) . PCR was carried out in a reaction volume of 25111containing CDM primers at 94°C for 30 s, 55°C for 60 s and noc for 2 min for 30 cycles in a thermal cycler (Perkin-Elmer/Cetus, Emeryville, CA) (15) . The primers used were 5'-CCAATGCCTTTGATGGACCA-3' (sense) and 5'-TG-TGAGTGTCCATCTGATIC-3' (antisense). Some resulting bands of RT-PCR were iden tified by Southern blotting , using the CDM probe, as being the cloned fragment described above. PCR amplification prod ucts were resolved by 7.5% polyacrylamide gel electrophoresis (PAGE) and stained with ethidium bromide . The total intensity of each resu lting band was measured with a densi tometer (Scanning Imager 300SX; Molecular Dynamics, Sunnyvale, CA) . The E/H ratio was represented by the ratio of the numerical value of CDME of CDMH.
STATISTICS
The chi-squared test was used where appropriate. The relationship between E/H ratio and tumor tissues and normal tissues was assessed by the Wilcoxon signed rank test. E/H ratios were compared with the clinicopathological features classified according to the General Rules for Gastric Cancer Study of the Japanese Research Society for Gastric Cancer (16) 
RESULTS
Because primers amplify across the site in the mRNA at which extra segme nts may be inserted to produce different forms of CDM, the interveni ng 'standard' portion of the molec ule will be amplified along with any transcripts from exons 1-10 spliced into it. The amplified fragment will be 334 bp if a sample expresses standard (hematopoietic) CDM (CDM H) only, a fragment of730 bp will be produced if it is the epithelial form of CD44 (CDME) and there will be several other fragments if a sample contains alternatively spliced transcripts (Fig. 1) . These appear as bands of differing molecular size when resolved by gel electrophoresis and Southern hybridization with CDM probes. PCR produced several amplification products (Fig. 2) and Southern blot analysis confirmed that all the bands corresponded to CDM isoforms.
CDM EXPRESSION IN GASTRIC CARCINOMA
CDMH was observed in all tumor tissues and adjacent non-cancerous mucosa, whereas CDME was detected in 69% (20 of 29) of the tumor tissues and in 40% (12 of 30) of adjacent non-cancerous mucosa. The difference between the two groups was significant (P < 0.05). Other splice variant forms were observed in 38% (11 of29) of the tumor tissues and in 13% (4 of 30) of non-cancerous mucosa. The average E/H ratios in gastric carcinoma and adjacent non-cancerous mucosa were 0.28 ± 0.16 and 0.17 ± 0.11. The E/H ratio in tumor tissues was significantly higher than in adjacent non-cancerous mucosa (P < 0.01 , Wilcoxon signed rank test) (Fig. 3) . There was no significant relationship between E/H ratio and histological type, depth of invasion, lymph node metastasis, blood vessel invasion, lymphatic vessel invasion, liver metastasis or peritoneal dissemination (Table 2) . Tumors with an E/H ratio of~0.28 were designated
. . -CD44H (334bp) months (mean 29 months), seven of IO patients with high E/H tumors had local recurrence or distant metastasis and died, whereas none of four patients with low E/H tumors did. The mean E/H ratios in gastric tumors from patients who died due to recurrence was 0.41 ±0.15, whereas that in surviving patients was 0.24 ± 0.20. The difference between the two groups was not significant (P =0.09) ( Table 3 ). The Kaplan-Meier curves show that patients with high E/l-Itumor s had a shorter survival time than those with low E/l-I tumors (P < 0.05 ) (Fig. 4) . Figure 4 . Kaplan-Meier analysis of overa ll survival in patients suffering from gastric carcinoma with low or high EIH ratio.
CD44E expression was predominantly observed in colorectal carcinomas compared to normal tissues (P < 0.05, X 2 test). Other splice variant forms were observed in 44% (10 of 23) of the tumor tissues and in 26% (five of 19) of non-cancerous muc osa. The average E/H ratios in colorectal carcinoma and adjacent non-cancerous mucosa were 0.66 ± 0.48 and 0.25 ± 0.22, respectively.
The E/H ratio in tumor tissues was significantly higher than in adjacent non-cancerous mucosa (P < 0.01, Wilcoxon signed rank test) (Fig. 3) . There was no significant relationship between E/H ratio and histological type, depth of invasion , lymph node metastasis, blood vessel invasion, lymphatic vessel invasion, liver metastasis or clinical stage ( There was no significant difference between two groups in clinical stages . During follow-up of 9-50 month s (mea n 37 month s), three of six patients with high E/H tumors had local recurrence or distant metastasis, compared with only two of 10 patients with low E/H tumors. Tumor-induced mortality was more frequent in high E/H ratio tumors (2/6 vs 0110, P = 0.05).
Th e mean E/H ratio of tumors from patients who died due to tumor recurrence was 1.21 ± 0.58, whereas that of tumors from surviving patient s was 0.57 ± 0.29. The difference between these two groups was significant (P < 0.05) ( Table 3 ). The KaplanMeier curves show that patients with high E/H tumors had a shorter survival time than those with low E/H tumors (P = 0.06) (Fig . 5) . (18) analyzed the expression of CD44v8-10 immunohistochemically using the antiCD44v8-10 monoclonal antibody and determined that it is a useful independent factor for prognosis in colorectal cancer. Tanabe et al. (19) reported that when CD44H was reintroduced into colon carcinoma cells, their in vitro and in vivo growth was significantly reduced. Miwa et al. (20) reported that the difference between E/H ratios of tumor tissue and adjacent non-cancerous mucosa correlated with lymph node metastasis, depth of invasion, blood vessel invasion and lymphatic vessel invasion in gastric carcinoma. We considered that a reduction of CD44H and an increase of CD44E may increase tumor growth rate and metastatic potential and CD44E/H ratio may be a prognostic factor. Using RT-PCR, we amplified CD44 obtained from human gastric and colorectal carcinoma, calculated the E/H ratio in cancer tissues and investigated the correlation between E/H ratio and clinicopathological parameters and survival. No significant association was found between E/H ratio and clinicopathological parameters and clinical stage. These findings differ from other authors' conclusions (20, 21) . In our studies, patients with liver metastases had higher E/H ratios than patients without liver metastases in colorectal carcinoma, but there was no significant difference. This may be due to the small number of patients with liver metastases in this study. After curative surgery, patients with high E/H ratios had poor prognosis due to tumor recurrence in colorectal and gastric carcinomas despite there being no significant difference in clinical stage between high and low E/H tumors. In gastric carcinoma multivariate analyses showed that the CD44 E/H ratio was not an independent prognostic factor (data not shown). In colorectal carcinoma multivariate analyses could not performed owing to the small number of patients who died. A larger study will help to clarify the independent prognostic significance of the E/H ratio. In univariate analyses the E/H ratio is a useful indicator in the prediction of the prognosis 100 --r-~---""""""""-"""'---L-"""
Survival (%)
At the time of operation we cannot predict perfectly the prognosis of operated patients by clinicopathological features alone. However, predictions may be made more accurately by investigating the expression of oncogene, tumor-suppressor gene and adhesion molecules which influence tumor growth and metastasis. Several groups have postulated that CD44 variant isoforms correlate with length of survival employing immunohistochemical methods. There have been no studies indicating that CD44 variant isoforms correlate with length of survival using molecular biology techniques. RT-PCR amplification resolved by PAGE can perform quantitative analysis, but immunohistochemical studies cannot. In this study we investigated whether the expression of CD44 variants influences tumor metastasis and can be a prognostic factor in gastric and colorectal carcinomas using RT-PCR.
Tanabe et al. (5) analyzed CD44 splice variants in specimens from normal colonic mucosa, primary colorectal cancers, normal of patients with gastric and colorectal carcinomas and III designing treatment regimens.
